LingVo.club
📖+10 XP
🎧+10 XP
+15 XP
Brown study suggests targeting mTORC2 could help fight cancer (Level A1) — a close up of a purple and red substance

Brown study suggests targeting mTORC2 could help fight cancerCEFR A1

26 Dec 2025

Adapted from Brown University, Futurity CC BY 4.0

Photo by National Cancer Institute, Unsplash

Level A1 – Beginner
2 min
80 words
  • Scientists at a university now study how cells send signals.
  • Cells use networks of proteins to sense their environment.
  • One important protein called mTOR controls different cell tasks.
  • mTOR works as two parts that do different jobs.
  • Many drugs stop both parts of mTOR at the same time.
  • Stopping one part can make cancer cells more resistant to treatment.
  • The new study shows we could block only one part.
  • This idea may help scientists design better cancer drugs in future.

Difficult words

  • scientistA person who studies and does research about nature
    Scientists
  • signalA sign or message from one thing to another
    signals
  • proteinA molecule in cells that does many jobs
    proteins
  • resistantNot easily affected by a drug or change
  • treatmentMedical care to try to cure or help

Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.

Discussion questions

  • Would you like to learn about cells and proteins?
  • Which would you prefer: a medicine that blocks one part or both parts?
  • Have you learned about proteins at school?

Related articles

HIF1 protein linked to tendon pain (Level A1)
28 Feb 2026

HIF1 protein linked to tendon pain

Researchers at ETH Zurich found that part of the HIF1 protein controls gene activity in tendon cells and can trigger tendinopathy. Experiments in mice and human tissue show HIF1 remodels collagen, makes tendons brittle and may cause pain.

Can Lost Vision Be Restored? (Level A1)
31 Dec 2025

Can Lost Vision Be Restored?

A new video with Juliette McGregor of the University of Rochester Medical Center explains that blindness is a spectrum. It looks at treatments, assistive support and ongoing research into retinal damage and future therapies.